Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
T-cell engagers
Biotech
Cullinan's $700M pact for BCMA bispecific to pair with other TCE
Cullinan is paying $20 million upfront for a BCMAxCD3 bispecific T-cell engager that the biotech plans to pair with its existing CD19 candidate.
James Waldron
Jun 5, 2025 4:38am
Juri inks $210M T-cell engager deal with China biotech
May 27, 2025 6:00am
German cancer antibody biotech eyes SPAC as route to Nasdaq
Apr 23, 2025 6:09am
ADCs to cell therapy: How AZ aims to 'redefine' oncology
Apr 9, 2025 11:44am
BioAtla lays off 30% of staff, hunts for ADC partners
Mar 28, 2025 6:30am
Immunocore bispecific reduces HIV reservoir in early trial
Mar 10, 2025 3:00pm
